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ABSTRACT
Introduction: People with diabetes are at
increased risk for heart failure (HF), major
adverse cardiovascular events (MACE) and
death following acute coronary syndromes
(ACS). It is important to recognize the most
powerful predictors of these events after an
ACS as early as possible, in order to
address them more aggressively. This is 
particularly important considering that 
various studies have shown that this popula-
tion is undertreated in the setting of ACS.
Objectives: To characterize a diabetic popu-
lation presenting with ACS and to determine
independent predictors of HF, MACE and
mortality on follow-up. 
Methods: This was a longitudinal, observa-
tional, retrospective study including 471
consecutive diabetic patients, both previ-
ously known and newly diagnosed, hospital-
ized for ACS in a single center between May
2004 and December 2006. A mean 12-
month follow-up was conducted. Cox regres-
sion analysis was used to determine the
independent predictors of HF, MACE and
mortality on follow-up, divided into different
periods – 1 month, 6 months and 1 year. 
Results: Of the overall diabetic population,
67.3% were male and mean age was 69±11
years. Mean glomerular filtration rate (GFR)
was 62±22 ml/min and mean left ventricular
Preditores de prognóstico adverso
numa população com diabetes após
síndromes coronárias agudas
RESUMO
Introdução: Os doentes com diabetes
apresentam elevado risco de desenvolver
insuficiência cardíaca (IC), eventos
cardiovasculares adversos major (MACE) e
morte após síndromes coronárias agudas
(SCA). É importante reconhecer, o mais
precocemente possível, os preditores mais
poderosos destes eventos após uma SCA, de
forma a adoptar uma abordagem terapêutica
mais agressiva. Isto é particularmente
relevante considerando que vários estudos
mostraram que esta população tem sido
subtratada no contexto de SCA. 
Objectivos: Caracterizar uma população
diabética com SCA e determinar preditores
independentes de IC, MACE e morte no
seguimento clínico. 
Métodos: Estudo longitudinal, observacional,
retrospectivo incluindo 471 doentes
diabéticos, com diagnóstico prévio ou
recém-diagnosticados, consecutivamente
hospitalizados por SCA num único centro
entre Maio de 2004 e Dezembro de 2006.
Foi efectuado um seguimento clínico
mediano de 12 meses. A análise de
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ejection fraction (LVEF) was 50%.
Diagnosis on admission was ST-elevation
myocardial infarction (STEMI) in 31.3%,
non-ST elevation myocardial infarction
(NSTEMI) in 50.1%, unstable angina (UA)
in 14.3% and ACS with left bundle branch
block or pacemaker in 4.2%. Cardiac
catheterization was performed in 55.6% of
the patients during the index hospitaliza-
tion. Mortality during hospitalization and at
1 year was 6.4% and 10.4%, respectively.
The one-year MACE rate was 20.4% and
hospitalization for HF occurred in 10.1% of
the patients. The independent predictors of
HF at 1 year were blood glucose on admis-
sion >184.5 mg/dl, GFR <63.8 ml/min,
LVEF <46.5% and NSTEMI, while predic-
tors of mortality were LVEF <40.5% and
Killip class on admission >I. Blood glucose
on admission >130.5 mg/dl and LVEF
<49.5% were independent predictors of
MACE, whereas cardiac catheterization was
a protective factor. 
Conclusion: Following ACS diabetic patients
have high rates of mortality, HF and MACE.
The low rate of invasive strategy may con-
tribute to this situation. HF during hospital-
ization, whether by low LVEF or Killip class
>I, and higher blood glucose on admission
were powerful predictors of poorer outcome.
Moreover, the use of recommended cardio-
vascular agents and procedures were protec-
tive factors. These findings suggest that dia-
betic patients should not be excluded from
recommended cardiovascular interventions.
Efforts should be made to identify these
high-risk patients as early as possible in
order to manage them carefully and aggres-
sively to improve their poor prognosis.
preditores independentes de IC, MACE e
morte no seguimento clínico, descriminados
por vários períodos – 1 mês, 6 meses e 1
ano. 
Resultados: Cerca de 67,3% da população
diabética total era do sexo masculino e a
idade média foi de 69 ± 11 anos. A taxa de
filtração glomerular (TFG) média foi de 62
± 22 ml/min e a fracção de ejecção do
ventrículo esquerdo (FEVE) média foi de
50%. Relativamente ao diagnóstico na
admissão, o enfarte agudo do miocárdio com
supradesnivelamento de ST (EAMCSST)
esteve presente em 31,3%, o enfarte agudo
do miocárdio sem supradesnivelamento de
ST (EAMSSST) em 50,1%, a angina instável
em 14,3% e o SCA com bloqueio completo de
ramo esquerdo ou pacemaker em 4.2%. Cerca
de 55,6% dos doentes foram submetidos a
cateterização cardíaca durante a referida
hospitalização. As taxas de mortalidade
durante a hospitalização e a 1 ano foram de
6,4% e 10,4%, respectivamente. A taxa de
MACE a 1 ano foi de 20,4% e a
hospitalização por IC ocorreu em 10,1% dos
doentes. Os preditores independentes de IC a
1 ano foram a glicemia na admissão > 184,5
mg/dl, TFG < 63,8 ml/min, FEVE < 46,5% e
EAMSSST, enquanto que os preditores de
mortalidade foram FEVE < 40,5% e classe
de Killip na admissão >1. Uma glicémia na
admissão > 130,5 mg/dl e FEVE <49,5%
foram os preditores independentes de MACE,
enquanto que a realização de cateterização
cardíaca foi um factor protector. 
Conclusão: A população com diabetes
apresenta elevadas taxas de mortalidade, IC
e MACE após SCA. O baixo recurso à
estratégia invasiva poderá contribuir para
esta situação. A IC durante a hospitalização,
revelada por baixa FEVE ou classe de
Killip > 1, e uma glicemia na admissão
elevada foram preditores poderosos de mau
prognóstico.  O uso dos agentes e
procedimentos cardiovasculares
recomendados foram factores protectores.
Estes dados sugerem que os doentes
diabéticos não devem ser excluídos das
intervenções cardiovasculares
recomendadas e que todo o esforço deve ser
INTRODUCTION
Diabetes is widely recognized as a powerfulrisk factor for cardiovascular disease.
People with diabetes are especially prone to
acute coronary syndromes (ACS) and heart
failure (HF), and cardiovascular disease is
their leading cause of death (1-4). The preva-
lence of diabetes is rising and recent projec-
tions point to an increase from 171 million in
2000 to 366 million worldwide by 2030 (5), with
“an expected” increase in the number of dia-
betic patients with coronary artery disease
(CAD) and HF(2, 4, 6, 7). Despite all advances in
ACS treatment, with consequent improve-
ments in prognosis in recent decades, diabet-
ic patients presenting with ACS remain a par-
ticularly high-risk population, with worse in-
hospital (1, 8-11) and long-term (2-4, 8, 9, 11-13) out-
comes. Diabetes was found to be an independ-
ent adverse prognostic factor after ACS(8, 9, 12, 13),
being associated with a twofold increase in
risk of death compared to their non-diabetic
counterparts (12). The development of acute HF
during the index hospitalization (1, 3, 8, 10) and
post-discharge (3, 11) contributes to this out-
come. This poor prognosis may be explained
by the inherent pathophysiology of diabetes,
the extent and severity of coronary artery dis-
ease in this population, the frequency of
comorbidities and also the underuse of the
recommended treatments in this subgroup (1, 4, 8-
10, 13). Although some data from registries and
controlled studies have shown benefits from
established cardiovascular strategies, diabetic
patients are usually under-represented in clin-
ical trials (4, 10). Despite the widespread recogni-
tion that people with diabetes are at increased
risk and have a dismal prognosis following ACS,
little is known regarding predictors of HF, major
adverse cardiovascular events (MACE) and
mortality after discharge in this population.
Because of the particularly high incidence of
these complications, it is important to recognize
their most powerful predictors as early as possi-
ble, in order to optimize the approach. The aim
of our study was to characterize a “real-world”
diabetic population presenting with ACS in
terms of baseline characteristics and treatment
patterns, to evaluate their in-hospital and fol-
low-up outcomes, and to determine independent
predictors of HF, MACE and mortality on fol-
low-up.
METHODS
Study design and patient population
This was a longitudinal, observational and
retrospective study including 471 diabetic
patients out of a total of 1329 patients consec-
utively admitted for ACS to a single intensive
coronary care unit, between May 2004 and
December 2006. Patients with both previous-
ly known and newly-diagnosed diabetes were
included. Diabetes was diagnosed during hos-
pitalization by an oral glucose tolerance test
(75 g) performed on the last day of hospitaliza-
tion. Patients with two-hour blood glucose 
≥200 mg/dl were classified as diabetic.
A database with standardized records was
used to characterize the overall diabetic pop-
ulation in terms of clinical and demographic
characteristics, cardiovascular risk factors, ACS 265
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feito para identificar estes doentes de alto
risco o mais precocemente possível, tratá-
-los cuidadosa e agressivamente de forma a
melhorar o seu pobre prognóstico. 
Palavras chave: 




Acute coronary syndromes; Prognosis
type, laboratory and electrocardiographic data,
evidence-based pharmacological agents (previ-
ous, at admission and at discharge) and interven-
tional therapies. Complications during hospital-
ization (including ventricular fibrillation, cardio-
genic shock, cardiac arrest, recurrent myocar-
dial infarction and acute pulmonary edema), as
well as length of hospital stay, were recorded.
An invasive strategy was defined as cardiac
catheterization performed during the first 72
hours of the index hospitalization, on either an
urgent or a non-urgent basis, followed by percu-
taneous coronary revascularization when indi-
cated and possible. Patients presenting with ST-
elevation myocardial infarction (STEMI) at our
center underwent primary angioplasty; only
those patients who were, at presentation, outside
the therapeutic window and had no clinical or
electrocardiographic signs of ischemia were
excluded. Generally, these patients also under-
went early cardiac catheterization (first 72
hours) during the index hospitalization.
Complete revascularization was defined as the
successful percutaneous revascularization of all
significant coronary lesions (≥75%) detected in
the main epicardial vessels.
Left ventricular ejection fraction was cal-
culated by echocardiography, using Simpson’s
biplane method.
A mean 12-month follow-up was conduct-
ed by telephone interview or personal commu-
nication. Rehospitalization for HF manage-
ment, unplanned revascularization or death
were recorded. HF during follow-up was
defined as hospitalization for signs and symp-
toms of HF. MACE was defined as the com-
bined result of cardiovascular death, non-fatal
myocardial infarction, re-admission for unsta-
ble angina (UA) or unplanned non-urgent per-
cutaneous coronary intervention (PCI), which
excludes PCI in the setting of a new ACS, at 1
month, 6 months and 1 year. The investigation
was conducted according to the principles
outlined in the Declaration of Helsinki.
Statistical analysis
Statistical analyses were performed using
SPSS version 13. Results are expressed as
mean ± standard deviation or quartiles for
continuous variables and as frequencies and
percentages for categorical variables. The fre-
quencies of categorical variables in the two
groups were compared by the chi-square test
or Fisher’s exact test. Continuous variables
were compared by the two-tailed Student’s t
test or the Mann-Whitney test. Independent
predictors of HF, MACE and mortality after
ACS were identified by multivariable Cox
regression analysis using the forward method
of variable selection (with a likelihood ratio
test). Predetermined clinically significant
variables were entered into the model: age,
gender, cardiovascular history (hypertension,
dyslipidemia, smoking status, previous stroke,
previous myocardial infarction, PCI, coronary
artery bypass graft surgery, peripheral vascular
and cerebrovascular disease); previous medica-
tion with aspirin, clopidogrel, angiotensin-con-
verting enzyme inhibitors (ACEIs), beta-block-
ers, calcium channel blockers, statins and
nitrates; total and LDL cholesterol; troponin
and CK-MB; heart rate and Killip class on
admission; body mass index; electrocardio-
graphic data (normal, left bundle branch
block [LBBB], atrial fibrillation [AF], sinus
rhythm); type of ACS (STEMI, non-ST eleva-
tion myocardial infarction [NSTEMI] or UA);
LVEF, GFR, admission blood glucose, cardiac
catheterization, medical treatment during the
initial 24 hours of hospitalization (aspirin,
clopidogrel, nitrates, beta-blockers, ACEIs,
calcium channel blockers, statins) and med-
ical treatment at discharge (aspirin, clopido-
grel, beta-blockers, statins and ACEIs).
Discrimination and calibration were evaluated
by the area under the receiver operating char-
acteristic curve and the Hosmer-Lemeshow
goodness-of-fit test, respectively. The Kaplan-
Meier method was used for cumulative sur-
vival analysis for each studied endpoint.
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diagnosed, was present in 35.4% of the cases
hospitalized for ACS in the study period,
stndy period, being previously known in
81.7% of these cases, and diagnosed for the
first time during hospitalization in the remain-
ing 18.3%. Of the total diabetic population
67.3% were male and mean age was
69.0±11.0 years. Hypertension and dyslipi-
demia were present in 80.5% and 80.7%,
respectively, and 12.1% were current smok-
ers. Previously known CAD was present in
64.5%, 21.8% had previous myocardial
infarction; 9.6% and 7.4% had undergone
percutaneous and surgical coronary revascu-
larization, respectively, while 4.0% had previ-
ously known HF, 7.9% previous stroke and
5.3% peripheral arterial disease. Diagnosis on
admission was STEMI in 31.3%, NSTEMI in
50.1%, UA in 14.3% and ACS with left 
bundle branch block or pacemaker in 4.2%
(Table I). Of the total diabetic population,
20.2% were previously on insulin and 42.6%
on oral hypoglycemic agents (Table IV).
Comparing the group undergoing a conser-
vative strategy with those undergoing an inva-
sive approach in terms of baseline character-
istics, we found that the former included a
higher proportion of women and the subjects
were older and had a longer known diabetes
duration and a higher prevalence of heart and
renal failure (Table II).
Hemodynamic, electrocardiographic
and laboratory data
Regarding hemodynamic data on admis-
sion, about 20.6% of the patients presented
with Killip class >1 and most had TIMI scores
between 2 and 4. Mean heart rate on admis-
sion was 80.0±16.0 bpm. On the baseline
ECG, LBBB was present in 6.8% of cases and
AF in 9.3%.
Concerning laboratory data, mean GFR
and blood glucose on admission were, respec-
tively, 62.2±22.3 ml/min and 169.0 (132.7-
224.3) mg/dl. Mean LVEF was 50.0±11%.
Table III presents details of hemodynamic,
electrocardiographic and laboratory parame-
ters in this population.
Catheterization laboratory results and
treatment patterns
Coronary angiography was performed in
55.6% of the patients, but only 46.7% actually
underwent complete revascularization. Among
these, stents were used in 65.9% and drug-
eluting stents were the choice in 71.9%. Of
those who underwent coronary angiography,
29.7% did not undergo PCI. Of these, 19%
underwent coronary artery bypass graft surgery
after discharge. Details of coronary lesions and
interventions are shown in Table IV.
Table V describes the medical treatment
used during the first 24 hours of hospitaliza-
tion and at discharge.
All patients presenting with blood glucose
>180 mg/dl on admission underwent intensive
insulin perfusion to obtain target blood glucose
between 90-140 mg/dl, in accordance with the
protocol in use in our coronary care unit (17). The
remaining patients were treated with low doses
of short-acting insulin, according to blood glu-
cose values determined at two-hour intervals.
In-hospital outcomes
The mean length of stay was 6.0±4.0 days.
About a third of the patients reached Killip
class >I during hospital stay. The rate of pre- 267
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Total number of patients 471
Demographic data
Male (%) 67.3
Mean age (years) (SD) 69.0±11.0
Type of ACS (%)
ST-elevation myocardial infarction 31.3
Non-ST elevation myocardial infarction 50.1
Unstable angina 14.3
Left bundle branch block / pacemaker 4.2
Cardiovascular risk factors (%)
Previously known diabetes 81.7




Stress / sedentary lifestyle 14.9
Family history of coronary artery disease 11.0
Cardiovascular history (%)
Myocardial infarction 21.8
Coronary artery disease 64.5
Percutaneous coronary intervention 9.6
Coronary artery bypass grafting 7.4
Stroke 7.9
Heart failure 4.0
Peripheral vascular disease 5.3
Table I. Baseline characteristics
SD: standard deviation
specified in-hospital complications was 8.3%
and mortality was 6.4% (Table VI).
Post-discharge outcomes
Follow-up was possible in 424 patients,
representing 90% of the total population.
MACE and mortality rates at 1-year follow-
up were, respectively, 20.4% and 10.4%. Of
the overall population 10.1% were hospital-
ized for HF. Follow-up event rates in the dif-
ferent periods considered are listed in Table
VI. Figures 1 and 2 represent the Kaplan-
Meier curves for survival and MACE-free sur-
vival at 1-year follow-up.
Predictors of poor outcome on 
follow-up
Patient characteristics were evaluated to
identify predictors of mortality, MACE and
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Invasive strategy Conservative strategy p
Total number of patients 262 209 -
Demographic data
Male (%) 73.7 59.3 0.001
Mean age (years) (SD) 66.0±10.0 73.0±9.0 <0.001
Type of ACS (%)
ST-elevation myocardial infarction 42.2 17.8 <0.001
Non-ST elevation myocardial infarction 37.5 65.8 <0.001
Unstable angina 16.3 11.9 0.179
Left bundle branch block / pacemaker 4.0 4.5 0.804
Cardiovascular risk factors (%)
Previously known diabetes 77.9 85.6 0.031
Newly diagnosed diabetes 22.1 14.4 0.031
Hypertension 79.2 82.1 0.476
Dyslipidemia 79.2 82.6 0.373
Smoking status 15.6 7.7 0.009
Cardiovascular history (%)
Myocardial infarction 80.8 74.4 0.120
Coronary artery disease 63.4 66.0 0.547
Percutaneous coronary intervention 12.1 6.3 0.042
Coronary artery bypass grafting 5.9 9.3 0.163
Stroke 6.9 9.1 0.365
Heart failure 1.4 8.0 0.029
Peripheral vascular disease 3.8 7.2 0.103
Glomerular filtration rate (ml/min) (P25-P75) 68.4 (55.6-81.9) 56.3 (41.1-72.1) <0.001
SD: standard deviation
Table II. Baseline characteristics – comparison between groups according to the selected strategy
Hemodynamic data 
Heart rate, (bpm) (SD) 80.0±16.0
Systolic blood pressure (mmHg) (SD) 141.0±26.0
Diastolic blood pressure (mmHg) (SD) 73.0±14.0
Killip class I at admission (%) 79.4
Killip class II at admission (%) 17.8
Killip class III at admission (%) 1.5
Killip class IV at admission (%) 1.3





Left bundle branch block 6.8
Laboratory parameters (P25-P75)
Peak troponin I (ng/ml) 10.2 (2.3-32.0)
Peak CK-MB mass (ng/ml) 29.9 (7.0-116.7)
Triglycerides (ng/ml) 149.0 (107.0-205.0)
LDL cholesterol (ng/ml) 123.0 (99.0-147.0)
HDL cholesterol (ng/ml) 40.0 (35.0-47.0)
HbA1c (%) 6.5 (6.0-8.2)
GFR (ml/min) 62.0 (42.0-84.0)
Admission blood glucose (mg/dl) 169.0 (132.8-224.3)
BMI (kg/m2) (SD) 28.6±5.3
Table III. Hemodynamic, electrocardiographic 
and laboratory data
Hb: hemoglobin; GFR: glomerular filtration rate; 
BMI: body mass index; SD: standard derivation
Catheterization during hospitalization 55.6















Table IV. Catheterization laboratory data (%)
HF development after an ACS. In multivariate
Cox regression analysis, the main independ-
ent predictors of HF at one year were blood
glucose on admission >184.5 mg/dl (OR
3.64), GFR <63.8 ml/min (OR 3.65), LVEF
<46.5% (OR 2.7) and NSTEMI (OR 2.86).
Independent predictors of mortality at one
year were LVEF <40.5% (OR 3.53) and Killip
class >I (OR 3.55) and independent predic-
tors of MACE at one year were blood glucose
on admission >130.5 mg/dl (OR 2.61) and
LVEF <49.5% (OR 1.83). An invasive strate-
gy was a protective factor against MACE (OR
0.53). The predictors of mortality, MACE and
HF for the different follow-up periods consid-
ered are listed in Tables VII and VIII.
DISCUSSION
Data from recent registries in Europe show
that diabetes prevalence among ACS patients
is increasing, presently ranging from 29 to
35% (12). This is in agreement with our results,
in which diabetic patients represent 35.4% of
the total ACS population, and is also compa-
rable to that observed in the CRUSADE reg-
istry (10). As previously reported by other
authors (4), undiagnosed diabetes was present
in a significant proportion of our population.
Diabetic patients are at particularly high risk
for cardiovascular events, as several studies
and registries have shown. GRACE(1) and
CRUSADE (10) revealed increased in-hospital
mortality compared with non-diabetics. The
Euro Heart Survey on Diabetes and the Heart
and the OASIS registry also reported, respec-
tively, increased 1 and 2-year mortality in dia-
betic patients with various presentations of
coronary disease (16, 17). In fact, some studies
have revealed that this mortality may be as
high as 7-18% at 30 days, 15-34% after 1
year, and up to 43% after 5 years (4). Although
diabetes status was not among the inclusion
criteria in the GRACE risk prediction tool, it
was included in the TIMI risk scores (12). In our
diabetic population the 1-year mortality rate
was 10.4%; although still high, this value is
slightly lower than those previously reported.
Current guidelines for management of ACS
(12) include special considerations for diabetic
patients. Several studies (11, 12, 18, 19), but not all (20,
21), have shown survival benefits from intensive
insulin infusion protocols in diabetic ACS
patients. European and American guidelines (4,
12, 22, 23) advocate tight glycemic control as soon
as possible, if necessary with insulin infusion,
in patients presenting with high glucose levels 269
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Previous treatment Medication in first 24 hours Medication at discharge
Aspirin (%) 40.1 96.4 89.4
Enoxaparin (%) - 96.2 -
Clopidogrel (%) 16.4 75.8 48.2
GP IIb/IIIa (%) - 57.3 -
Beta-blockers (%) 22.1 78.6 78.6
ACEIs (%) 45.4 93.2 89.0
Statins (%) 32.2 97.0 95.8
Diuretics (%) 27.8 38.2 MD
Nitrates (%) 22.7 40.8 MD
Ezetimibe (%) MD 8.9 8.9
OHA (%) 42.0 32.0 MD
Insulin (%) 21.5 76.3 MD
Table V. Pharmacological treatment 
GP IIb/IIIa: glycoprotein IIb/IIIa inhibitors; ACEIs: angiotensin-converting enzyme inhibitors; OHA: oral hypoglycemic agents; ND: no
data.
MD: missing data.
In-hospital complication rate (%) 8.3
In-hospital mortality rate (%) 6.4
Mortality at 30 days (%) 3.1
Mortality at 6 months (%) 7.5
Mortality at 1 year (%) 10.4
MACE at 30 days (%) 7.2
MACE at 6 months (%) 16.3
MACE at 1 year (%) 20.4
Heart failure - 1 year (%) 10.1
Table VI. Endpoints In-hospital and on follow-up 
MACE: major adverse cardiovascular events
(serum glucose >180 mg/dl). Although the target
glucose levels are not well defined, a reasonable
goal was considered to be near-normal blood
glucose (90-140 mg/dl). “Nevertheless, recent
studies have drawn attention to the inherent
risks of hypoglycemia in these high-risk sub-
jects, leading to the proposal of more moderate
glycemic levels.”
Some reports have shown an additional
protective role for the recommended cardio-
vascular drugs in this population. Although a
major specific secondary prevention trial has
not yet been conducted in a diabetic popula-
tion, subgroup analysis from statins trials
showed similar benefits to non-diabetics in
coronary event reduction; these drugs are
therefore recommended for all diabetic
patients with cardiovascular disease, regard-
less of lipid profile(4). Similar results have
been found with ACEI trials, leading to their
indication in this context(4). Beta-blockers
have been shown to reduce mortality and new
coronary events, supporting their recommen-
dation in tåhis setting (4). However, beta-block-
ers have often been withheld (4) due to con-
cerns over potential deterioration of metabolic
control and blunting of hypoglycemia aware-
ness and response(9, 13). Finally, the addition of
clopidogrel to aspirin is also proposed as a
result of studies that have proved its benefit(4).
Regarding medical therapy and the interna-
tional guidelines, we noticed in our population
a low rate of prescription of the main cardio-
vascular drugs, particularly clopidogrel and
beta-blockers, although we have no informa-
tion on potential contraindications that could
have limited their use. Explanations for the
low rate of prescription of antiplatelet therapy
may be the existence of gastrointestinal dis-
ease or the possibility of bleeding complica-
tions during hospitalization or in the future
due to double antiplatelet therapy in an elder-
ly and renally impaired population. The use of
statins was a protective factor for the inci-
dence of MACE at 6 months and mortality at
30 days, an observation in agreement with the
studies referred to above, highlighting the
importance of optimized medical treatment. It270
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OR CI p
Mortality at 30 days
LVEF <39.5% 15.45 3.05-78.35 0.001
BMI <29.7 kg/m2 0.10 0.02-0.57 0.009
Statins during hospitalization 0.06 0.01-0.63 0.019
Mortality at 6 months
LVEF <40.5% 3.27 1.30-8.27 0.012
Heart rate >101.5 bpm 3.96 1.57-10.03 0.004
Killip class >I 3.67 1.51-8.89 0.004
Mortality at 1 year
LVEF <40.5% 3.53 1.69-7.40 0.001
Killip class >I 3.55 1.70-7.40 0.001
MACE at 30 days
Female 0.34 0.13-0.92 0.033
Invasive strategy 0.43 0.21-0.90 0.026
MACE at 6 months
Previous medication with statins 0.34 0.14-0.82 0.016
Invasive strategy 0.51 0.26-0.98 0.044
LVEF <51.5% 1.84 0.94-3.58 0.075
MACE at 1 year
Invasive strategy 0.53 0.31-0.91 0.021
Admission blood glucose >130.5 mg/dl 2.61 1.11-6.10 0.027
LVEF <49.5% 1.83 1.07-3.14 0.028
Heart failure at 1 year
Admission blood glucose >184.5 mg/dl 3.64 (1.65-8.06) 0.001
GFR <63.8 ml/min 3.65 (1.70-7.83) 0.001
LVEF <46.5% 2.7 (1.14-6.37) 0.023
NSTEMI 2.86 (1.23-6.60) 0.014
CI: 95% confidence interval; BMI: body mass index; LVEF: left ventricular ejection fraction; GFR: glomerular filtration rate; NSTEMI:
non-ST elevation myocardial infarction.
Table VII. Independent predictors of mortality on follow-up
is, therefore, reasonable to assume that the
prognosis of this diabetic population may be
further improved by more frequent utilization
of the recommended cardiovascular treat-
ments.
Despite the considerable improvements in
ACS treatment in recent years and the current
international recommendations for this high-
risk population, several registries and studies
have shown that, similarly to our results, this
population has paradoxically been undertreat-
ed, benefiting less frequently from medical and
revascularization procedures, which could part-
ly account for their worse prognosis (1, 4, 8-10, 12, 13).
Several studies have shown that there is actu-
ally no reason to expect an increased rate of
side-effects in people with diabetes, although
most information comes from subgroup analy- 271
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Figure 1. Kaplan-Meier curve for 1-year survival



























sis of larger trials and not from specific trials
involving diabetic populations (4). Nonetheless,
comparison of the results of Euro Heart
Survey ACS I with Euro Heart Survey ACS II
points towards a positive temporal trend in
this context (8, 24).
Similarly to previous registries, in terms of
the international guidelines, in our diabetic
population we found lower-than-expected
rates of revascularization procedures. A possi-
ble explanation for this undertreatment (and
also the rate of conservative strategy in some
of our patients presenting with STEMI) could
be delayed diagnosis of ACS due to atypical
presenting symptoms which narrowed the
therapeutic window for some interventions.
Another possible reason is that people with
diabetes are thought to be more vulnerable
and considered to have a relative contraindi-
cation for some treatments (4). Diabetic patients
frequently have several comorbidities, which
may contraindicate some of the recommended
treatments such as revascularization proce-
dures. In our population, patients undergoing
a conservative strategy were older and had
lower GFR, which may have contributed to
this therapeutic option. Furthermore, we have
no information on patient preferences that
may have influenced some decisions regard-
ing invasive interventions. We can speculate
that, due to the above-mentioned baseline
characteristics and due to longer known dia-
betes duration, patients undergoing a conser-
vative strategy may have a similar or even
higher rate of significant coronary disease,
compared to patients undergoing an invasive
approach. Moreover, we should take into
account that an invasive strategy was a protec-
tive factor against the incidence of MACE in
all follow-up periods considered, which is in
agreement with previous results concerning
its benefits (4, 12). These findings highlight the
need to put into practice the international
guidelines in order to improve the prognosis of
this population.
A significant proportion of our diabetic
population had previous known CAD and
some were known to have CAD not suitable for
revascularization. This, in addition to the fact
that some patients had normal coronary anato-
my, could partially explain the low rate of
revascularization in the index hospitalization.
The rate of CABG was even lower, probably
because most patients underwent PCI in the
context of STEMI. Among the remainder, PCI
was the procedure of choice in our depart-
ment if the coronary lesions were suitable.
There is an ongoing controversy regarding the
optimal approach for coronary revasculariza-
tion in diabetic patients. Although some stud-
ies have shown a less favorable prognosis
with PCI, they were not conducted in the era
of modern stents, and some of them involved
stable CAD patients (4, 12). The availability of
newer stents and adjuvant antithrombotic
therapy has improved the angiographic suc-
cess of PCI in diabetic patients, even those
with multivessel disease. In fact, some recent
studies using these more modern revascular-
ization approaches did not confirm earlier
reports regarding mortality, although it
appeared that diabetic patients more often
had further revascularization procedures in
the PCI arm (4, 12). Further studies are therefore
needed to determine the optimal revascular-
ization strategy in diabetic patients.
Numerous factors regarding the patho-
physiology of diabetes may contribute to this
poorer outcome, such as hyperglycemia-
induced toxicity with consequent vascular
damage and impaired collateral vessel forma-
tion (9), endothelial dysfunction, increased
platelet activity (3), decreased vasodilatory
reserve and fibrinolysis, elevated platelet
aggregability (4) and autonomic neuropathy (1, 4,
10, 11), the latter potentially being responsible
for ventricular arrhythmias(1). Specific aspects
of this condition, such as the occurrence of
widespread and diffuse coronary artery dis-
ease, small vessel disease and diabetic car-
diomyopathy (4, 9, 13), may also play an important
role. Diabetic patients have more comorbid
conditions, including renal dysfunction,
hypertension, prior HF and myocardial
infarction, obesity, stroke and vascular dis-
ease, further contributing to their dismal
prognosis (3, 4, 12). As previously stated, our dia-
betic population had a high prevalence of car-272
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diovascular risk factors and comorbidities,
and notably, they had also a high prevalence
of previous CAD.
Diabetic patients are also at increased risk
for developing HF both during hospitalization
(1, 8, 9) and after discharge(8, 9). HF in these
patients has a complex and multifactorial eti-
ology that results from a constellation of
pathophysiologic processes. It has been tradi-
tionally attributed to the concurrent presence
of ischemic or hypertensive heart disease (6).
However, diabetic cardiomyopathy, a distinct
entity that has been described as myocardial
dysfunction that occurs independently of CAD
or hypertension, adds to HF development in
this population; as a consequence, both dias-
tolic and systolic dysfunction may occur (1, 7);
some antidiabetic drugs have also been impli-
cated (1). Not only are diabetes and HF often
associated; this association carries an
extremely adverse outcome, with substantially
higher mortality and recurrent hospitalization,
especially in patients with ischemic car-
diomyopathy (6).
Several studies in ACS populations have
shown that the incidence of HF is a strong
predictor of subsequent mortality (4, 12, 15). In our
population, systolic dysfunction was, in fact,
the most powerful predictor of adverse out-
come, leading to HF, MACE and death after
discharge in all follow-up periods considered.
Furthermore, Killip class >I, reflecting HF on
admission, with either systolic or diastolic
dysfunction, was a potent predictor of mortal-
ity. This implies that every effort should be
made to treat these patients carefully and as
early as possible, particularly with reperfusion
strategies and drugs that have been demon-
strated to improve HF prognosis.
NSTEMI was another predictor of HF in
follow-up, reflecting the lower use of an inva-
sive strategy in this type of ACS compared
with STEMI.
The median HbA1c value was not very
high, possibly indicating acceptable blood
glucose levels in the weeks before admission.
However, some authors (23) propose that a high
admission glucose level could reflect the
degree of glycemic control in the outpatient
setting, which could explain the link between
outpatient glycemic control and outcomes in the
inpatient population. Higher blood glucose on
admission was an independent predictor of HF
(above 184 mg/dl) and MACE at one year (above
130 mg/dl). This was in agreement with previous
studies indicating that admission blood glucose
levels in diabetic ACS patients were an inde-
pendent risk factor of poor outcome in both the
short and long term (4, 12, 20, 26-30). It also shows the
importance of the recommended measures to
lower high blood glucose values as soon as pos-
sible, as was the practice in our center.
LIMITATIONS
It was not possible in our database to dif-
ferentiate types of diabetes and no information
was available regarding the known duration of
the disease.
It was also not possible to identify the tim-
ing of cardiac catheterization during the index
hospitalization. We have no information about
possible patient preferences, which may have
influenced some decisions regarding the actu-
al choice of procedures, particularly invasive
interventions. In the same way, we have no
data regarding possible bleeding complica-
tions or contraindications to the prescribed
medications, which could be relevant to the
interpretation of the prescription rates.
We also have no data regarding hypo-
glycemic agents prescribed at discharge and
during follow-up, and we could not obtain infor-
mation on diabetes control in the 12-month fol-
low-up, both of which constitute an important
limitation of our study.
There were no data regarding the occur-
rence of elective percutaneous revasculariza-
tion procedures after discharge, which could
have affected the results. However, it is impor-
tant to note that in the majority of our patients,
when indicated and when lesions suitable for
revascularization were present, the procedure
took place during the first hospitalization,
minimizing potential bias.
It was not possible to obtain information
regarding follow-up in 10% of the population,
which we recognize to be a limitation of our study. 273
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Finally, this was an observational and non-
randomized study, with the inherent limita-
tions.
CONCLUSION
Diabetes is common among ACS patients
and these patients have a high incidence of
MACE, HF and mortality at 1-year follow-up.
This poor outcome could be partially
explained by the relatively low utilization of
the recommended cardiovascular agents and
revascularization procedures. An invasive
strategy and statins were protective factors,
while systolic dysfunction, high Killip class
and high blood glucose were the most consis-
tent predictors of worse prognosis. These data
show that more extensive use of established
treatments may have the potential to improve
the picture of diabetic patients presenting
with ACS. Diabetes should be more carefully
considered in the risk stratification of ACS
patients. Our results also highlight the need
for research to identify effective strategies to
manage ACS in this high-risk population.
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